Vitreoretinal Surgery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The vitreoretinal surgery devices market size is expected to increase from USD 733.62 million in 2025 to USD 762.12 million in 2026 and reach USD 919.86 million by 2031, growing at a CAGR of 3.74% over 2026-2031. This report is Segmented by Product Type (Perfluorocarbon Liquids, Endo-Illumination Instruments, and More), Surgery Type (Posterior, Anterior), Technology (20/23-Gauge, 25/27-Gauge), End User (Hospitals, Ascs, Ophthalmology Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Vitreoretinal Surgery Devices Market Trends and Insights

Rising Prevalence of Diabetic Retinopathy & AMD

Diabetic retinopathy affected 103.12 million adults in 2025, while age-related macular degeneration reached 195.92 million cases, creating a durable pipeline for complex retinal procedures. China’s Healthy China 2030 program increased rural retinal screening coverage to 54% by 2025, resulting in a 22% boost in newly diagnosed proliferative cases. India’s National Programme for Control of Blindness reported that diabetic eye disease prevalence climbed to 21.3 % among known diabetics in 2025, lengthening specialist wait times in tier-2 cities. In North America, rising obesity rates sustain incident diabetes, keeping procedure backlogs elevated. These epidemiological trends are driving the expansion of the vitreoretinal surgery devices market, as hospitals and ASCs invest in additional consoles and consumables to meet the growing demand.

Shift Toward Single-Use Ophthalmic Instruments Driven by Strict Infection-Control Mandates

The 2024 CDC guideline reclassified reusable endo-illuminators as critical devices that require sterilization between cases, a standard many sterile-processing departments struggle to meet. U.S. retina services responded by shifting to pre-sterilized disposable light pipes and cutters, prompting a 41% surge in Alcon’s disposable sales during Q3 2025. The EU Medical Device Regulation’s traceability rules added paperwork for reusables, accelerating the adoption of single-use products in high-volume centers in Germany and France. Bausch + Lomb’s Stellaris Elite platform capitalized on the trend by bundling 25-gauge disposable packs that eliminate reprocessing liability, capturing 18% of the U.S. ASC segment in 2025. As urban APAC hospitals emulate Western infection-control standards, the penetration of single-use products is rising in Singapore, Seoul, and tier-1 Chinese cities.

High Capital & Consumable Costs

A fully configured vitrectomy suite costs USD 250,000 to USD 450,000, a figure that excludes 68% of U.S. independent retina practices from ownership. Single-use packs add USD 800 to USD 1,200 per case, versus USD 200 to USD 300 for reusables after reprocessing labor, straining margins in low-income markets. In India, consumables account for 42% of procedure costs, which limits adoption in tier-2 and tier-3 cities, where out-of-pocket payments dominate. DORC’s EVA NEXUS, launched at USD 180,000, aims to bridge the gap with modular upgrades but commands slow uptake, as surgeons prioritize entrenched Alcon and Bausch ecosystems. While leasing models, such as Alcon’s OptiLease, spread costs over 36 months, only 10% of practices have adopted them due to the perceived risk of obsolescence.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Outpatient/ASC Vitreoretinal Procedures
• Intra-Operative OCT & Digital Visualization Uptake
• Patchy Reimbursement for Premium Kits

Segment Analysis

Single-use consumables expanded their share of the vitreoretinal surgery devices market in 2025 and are forecast to grow at a 6.76% annual rate through 2031, while vitrectomy consoles accounted for 34.81% of the revenue. Prefilled silicone-oil syringes trimmed eight minutes of prep time per case and cut contamination risk, propelling adoption among ASCs focused on fast turnover. Endo-illumination is shifting toward disposable LED light pipes, with 58% of Bausch’s 2025 sales projected to come from single-use units. Perfluorocarbon liquids remain a niche but steady earner; Vitreq’s extended-duration formulation, CE Marked in 2024, lengthened tamponade dwell time and postponed follow-up surgeries.

The momentum of consumables hinges on infection-control mandates and the economics of ASCs, where reprocessing space is at a premium. The vitreoretinal surgery devices market for disposables is projected to expand further as CDC and EU regulators scrutinize validation data for reusable devices. Meanwhile, console vendors stress backward compatibility; Alcon’s Unity system allows legacy Constellation owners to migrate gradually by adding disposable gauge-specific cassettes. Carl Zeiss Meditec bundles microscopes with OCT modules to secure long-term consumable revenue, mirroring the printer-ink razor model that stabilizes cash flow.

Posterior procedures continued to dominate, accounting for 69.03% of the revenue in 2025; however, anterior vitrectomy volumes increased by 7.20% annually due to pediatric trauma and cataract-related complications. The vitreoretinal surgery devices market size for anterior cases benefits from cross-utilizing the same 27-gauge cutters used posteriorly, minimizing inventory SKUs for ASCs. A 27-gauge anterior approach cut surgical time by 12 minutes compared to a 20-gauge approach, lowering anesthesia exposure in children and aligning with ASC session economics. Posterior cases, although slower-growing, account for 82% of consumable spend, as they require more forceps, scissors, and retinal tamponades.

Medicare’s 2025 site-neutral reforms further erased inpatient-outpatient divides, encouraging same-day discharge even for posterior repairs. Ophthalmologists increasingly refer complex anterior complications to retina specialists, concentrating volume in high-throughput centers that specify disposable kits. BVI and Katalyst Surgical now offer sub-USD 400 anterior vitrectomy packs that align with payor bundles, reinforcing consumable tailwinds for the vitreoretinal surgery devices market.

Complete Report Scope:

• By Product Type
  • Perfluorocarbon Liquids
  • Endo-illumination Instruments
  • Vitreoretinal Prefilled Silicone-Oil Syringes
  • Vitrectomy Systems
  • Single-use Consumables
  • Other Product Types
• By Surgery Type
  • Posterior Vitreoretinal Surgery
  • Anterior Vitreoretinal Surgery
• By Technology
  • 20/23-Gauge Conventional Systems
  • 25/27-Gauge Micro-incision Systems
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Ophthalmology Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.16% of 2025 revenue, anchored by Medicare’s willingness to reimburse digital visualization and high ASC penetration. The United States alone placed 230 new vitrectomy consoles in 2025, with 64% of these going to ASCs. Canada continues to favor hospital outpatient departments but is trialing bundled-payment pilots that could speed ASC licensing by 2027.

Asia-Pacific is the fastest-growing territory, advancing at a 7.74% CAGR through 2031. Medical tourism drew 47,200 inbound ophthalmic cases to Thailand in 2025, while India’s National Health Mission funded 140 district-hospital vitrectomy systems that same year. China’s NHSA cataloged 12 reimbursable retinal codes in 2025, reimbursing 85% of the patient's cost and igniting demand for consoles in tier-2 urban clusters. Collectively, these initiatives expand the vitreoretinal surgery devices market and shift unit placement growth toward APAC.

Europe’s growth is hindered by flat DRG tariffs and stringent EU MDR rules, which extend approval timelines and delay the launch of new-gauge and single-use products. Backlog pressures in Germany, the United Kingdom, and France are pushing clinics in Eastern Europe to adopt lower-cost 23-gauge systems, which could moderate regional ASPs. The Middle East and Africa are growing at a rate of 6.2% per year, buoyed by the Gulf Cooperation Council's hospital privatization and South Africa’s expansion of its private-hospital network. South America faces currency volatility; Brazil’s public SUS system reimburses only basic 20-gauge kits, shifting premium demand to self-pay urban clinics. Australia, while minor, approved intra-operative OCT for reimbursement in 2025, underscoring its early-adopter profile.

List of Companies Covered in this Report:

• Alcon
• ASICO
• Bausch Health
• BVI (Beaver-Visitec)
• Carl Zeiss
• D.O.R.C. USA
• Dutch Ophthalmic Research Center International
• GEUDER
• HOYA / Pentax Medical
• IRIDEX
• Johnson & Johnson
• Katalyst Surgical
• Danaher
• MedOne Surgical
• Nidek
• OCULUS Optikgeräte
• Optos
• Peregrine Surgical
• Synergetics
• Topcon
• Vitreq
• Ziemer Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support